Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
NCT01127750
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2417
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG:
FTY720
Sponsor
Novartis